Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

17:53
08/19/19
08/19
17:53
08/19/19
17:53

Sarepta falls over 4% or $5.31 to $115 per share after FDA's golodirsen response

  • 19

    Aug

SRPT Sarepta
$120.16

-4.81 (-3.85%)

08/08/19
PIPR
08/08/19
NO CHANGE
PIPR
Sarepta selloff on FAERS report 'smells fishy,' says Piper Jaffray
Shares of Sarepta Therapeutics dropped over 12% before being halted following news of a FDA Adverse Event Reporting System report that a patient was hospitalized with rhabdomyolysis after being administered their Duchenne muscular dystrophy gene therapy, Piper Jaffray analyst Danielle Brill tells investors in a research note. This "whole thing smells fishy," considering the event occurred in February 2019, the FAERS database is not intended for investigational drugs, and DMD patients are at an increased risk for rhabdomyolysis, says the analyst. She believes it is more likely that the event was related to the disease than Sarepta's gene therapy treatment. Brill has an Overweight rating on Sarepta, which halted for news this afternoon down $17.94 to $124.32.
08/09/19
FBCO
08/09/19
NO CHANGE
Target $207
FBCO
Outperform
Credit Suisse says 'no change' to Sarepta thesis on SRP-9001 FAERS event
Credit Suisse analyst Martin Auster said there is "no change" to his thesis on Sarepta Therapeutics after speaking with the company's management after the company said that an adverse event report was erroneously submitted to the FDA's adverse event reporting system, or FAERs. In a research note to investors, Auster, who has an Outperform rating and $207 price target on Sarepta shares, says management said the patient in question was reported to have been highly active the previous day and subsequently presented to his clinician with dark urine, elevated CK, no muscle pain and was otherwise asymptomatic. Management said that the urine and CK measures resolved to baseline and the patient was discharged from the hospital on the next day. Auster says overall, he thinks the reported AE concern was a non-event and that the lack of any DSMB or FDA action as a result strengthens the credibility of the company's position.
08/16/19
CHDN
08/16/19
UPGRADE
Target $10
CHDN
Buy
Chardan upgrades Solid Biosciences to Buy after IGNITE DMD trial update
As previously reported, Chardan analyst Gbolahan Amusa upgraded Solid Biosciences (SLDB) to Buy from Neutral after the company provided an update on the IGNITE DMD phase I/II study of its AAV-based gene therapy, SGT-001, for Duchenne muscular dystrophy. The company's update and trial protocol changes suggest to the analyst that concerns on SGT-001 may be addressable, which may mean Solid is still positioned to address potential manufacturing constraints in the AAV-based gene therapy DMD space. Amusa noted that Sarepta Therapeutics (SRPT) utilizes less-scalable adherent processes that may limit supply and may mean Sarepta's product could cost more per patient to manufacture. Amusa raised the price target on Solid shares to $10 from $7.50.
08/19/19
LEER
08/19/19
UPGRADE
Target $15
LEER
Outperform
Solid Biosciences upgraded to Outperform with $15 target at SVB Leerink
As previously reported, SVB Leerink analyst Joseph Schwartz upgraded Solid Biosciences (SLDB) to Outperform from Market Perform after reassessing the protocol amendments and enrollment progress communicated by the company for its Phase 1/2 IGNITE-DMD trial. He believes much of the concerns that have weighed on the stock are baked-in at this point and continues to believe that Solid's scalable manufacturing "could be an underappreciated X-factor" that could potentially help it catch-up to the leader in the DMD space, Sarepta (SRPT). Schwartz raised his price target on Solid shares to $15 from $8.

TODAY'S FREE FLY STORIES

AAPL

Apple

$217.69

-3.22 (-1.46%)

16:45
09/20/19
09/20
16:45
09/20/19
16:45
Periodicals
Breaking Periodicals news story on Apple »

Apple given tariff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDA

IDACORP

$111.26

0.93 (0.84%)

16:36
09/20/19
09/20
16:36
09/20/19
16:36
Hot Stocks
IDACORP raises quarterly dividend to 67c from 63c per share »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

MO

Altria Group

$40.80

0.69 (1.72%)

16:33
09/20/19
09/20
16:33
09/20/19
16:33
Hot Stocks
Altria Group recommends rejection of amended mini-tender by TRC »

Altria Group states it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$0.00

(0.00%)

, AL

Air Lease

$42.68

-0.615 (-1.42%)

16:32
09/20/19
09/20
16:32
09/20/19
16:32
Hot Stocks
Air Lease announces delivery of new A321-200neo to Air Astana »

Air Lease Corporation…

EADSY

Airbus

$0.00

(0.00%)

AL

Air Lease

$42.68

-0.615 (-1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

16:30
09/20/19
09/20
16:30
09/20/19
16:30
Options
Preliminary option volume of 23.5M today »

Preliminary option volume…

PSX

Phillips 66

$103.26

0.14 (0.14%)

16:28
09/20/19
09/20
16:28
09/20/19
16:28
Periodicals
Phillips 66 says Beaumont oil terminal ops still shut down, Reuters says »

Phillips 66 said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

POST

Post Holdings

$105.73

0.335 (0.32%)

16:24
09/20/19
09/20
16:24
09/20/19
16:24
Hot Stocks
Post files IPO for active nutrition unit BellRing Brands »

Post Holdings, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
09/20/19
09/20
16:20
09/20/19
16:20
Options
Closing CBOE SPX and VIX Index summary for September 20th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELS

Equity Lifestyle

$134.26

1.22 (0.92%)

16:19
09/20/19
09/20
16:19
09/20/19
16:19
Hot Stocks
Equity Lifestyle announces two-for-one stock split »

Equity Lifestyle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
09/20/19
09/20
16:17
09/20/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$13.52

-0.11 (-0.81%)

16:16
09/20/19
09/20
16:16
09/20/19
16:16
Hot Stocks
Fiat Chrysler COO Paul Alcala to retire effective September 30 »

Fiat Chrysler Automobiles…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
09/20/19
09/20
16:16
09/20/19
16:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLS

Sellas Life Sciences

$0.13

-0.0017 (-1.29%)

16:15
09/20/19
09/20
16:15
09/20/19
16:15
Syndicate
Breaking Syndicate news story on Sellas Life Sciences »

Sellas Life Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDG

TransDigm

$527.88

-4.44 (-0.83%)

16:11
09/20/19
09/20
16:11
09/20/19
16:11
Hot Stocks
TransDigm provides update on divestitures »

TransDigm Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

16:10
09/20/19
09/20
16:10
09/20/19
16:10
General news
Treasury Market Summary »

Treasury Market Summary:…

AAPL

Apple

$218.51

-2.4 (-1.09%)

, MCD

McDonald's

$210.05

-0.51 (-0.24%)

16:08
09/20/19
09/20
16:08
09/20/19
16:08
On The Fly
Fly Intel: Wall Street's top stories for Friday »

U.S. markets closed out…

AAPL

Apple

$218.51

-2.4 (-1.09%)

MCD

McDonald's

$210.05

-0.51 (-0.24%)

FB

Facebook

$189.46

-0.69 (-0.36%)

FIT

Fitbit

$4.13

0.46 (12.55%)

GOOG

Alphabet

$1,230.65

-8.95 (-0.72%)

GOOGL

Alphabet Class A

$1,230.42

-7.79 (-0.63%)

WMT

Walmart

$116.92

-0.12 (-0.10%)

MO

Altria Group

$40.78

0.67 (1.67%)

BTI

British American Tobacco

$36.29

-0.21 (-0.58%)

IMBBY

Imperial Brands

$0.00

(0.00%)

PM

Philip Morris

$71.50

-0.2 (-0.28%)

MDR

McDermott

$2.02

0.44 (27.85%)

CRC

California Resources

$11.08

1.18 (11.92%)

ROKU

Roku

$107.49

-26.22 (-19.61%)

W

Wayfair

$122.82

-5.845 (-4.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Oct

  • 12

    Nov

  • 13

    Nov

  • 14

    Nov

BPMX

BioPharmX

$0.39

0.008 (2.12%)

16:08
09/20/19
09/20
16:08
09/20/19
16:08
Hot Stocks
BioPharmX receives extension to regain compliance with NYSE »

BioPharmX received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKIS

Peak Resorts

$10.99

0.005 (0.05%)

, MTN

Vail Resorts

$235.28

1.31 (0.56%)

16:06
09/20/19
09/20
16:06
09/20/19
16:06
Hot Stocks
Peak Resorts holders approve merger pact for acquisition by Vail Resorts »

Peak Resorts, Inc. (SKIS)…

SKIS

Peak Resorts

$10.99

0.005 (0.05%)

MTN

Vail Resorts

$235.28

1.31 (0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 26

    Sep

SPKE

Spark Energy

$10.07

0.06 (0.60%)

16:04
09/20/19
09/20
16:04
09/20/19
16:04
Syndicate
Breaking Syndicate news story on Spark Energy »

Spark Energy files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPKE

Spark Energy

$10.07

0.06 (0.60%)

16:02
09/20/19
09/20
16:02
09/20/19
16:02
Syndicate
Breaking Syndicate news story on Spark Energy »

Spark Energy files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTFT

Future FinTech

$1.01

-0.02 (-1.95%)

16:01
09/20/19
09/20
16:01
09/20/19
16:01
Hot Stocks
Future FinTech submits compliance plan to Nasdaq »

Future FinTech Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SALM

Salem Media

$1.65

-0.115 (-6.52%)

15:34
09/20/19
09/20
15:34
09/20/19
15:34
Syndicate
Breaking Syndicate news story on Salem Media »

Salem Media files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SALM

Salem Media

$1.65

-0.115 (-6.52%)

15:34
09/20/19
09/20
15:34
09/20/19
15:34
Syndicate
Breaking Syndicate news story on Salem Media »

Salem Media files $40M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRC

Bank of Marin

$42.89

-0.63 (-1.45%)

15:31
09/20/19
09/20
15:31
09/20/19
15:31
Hot Stocks
Bank of Marin engages Korn Ferry for CEO successor search »

Bank of Marin and its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIG

Transocean

$5.78

-0.08 (-1.37%)

15:30
09/20/19
09/20
15:30
09/20/19
15:30
Options
Long-term deep otm puts in Transocean see action »

Long-term deep otm puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.